CAS No.
[57149-07-2(Unlabeled)]
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
Naftopidil-d7, 57149-07-2(Unlabeled)
Application Notes
Useful research chemical for a range of applications
Hazard Compound
Refer MSDS for complete information
Naftopidil-d7 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Naftopidil-d7 usage and description
Naftopidil D7 is a deuterated analogue of the drug Naftopidil, which is commonly used in the treatment of benign prostatic hyperplasia (BPH). Naftopidil D7 is a selective alpha-1 adrenoceptor antagonist, which means it blocks the action of the alpha-1 receptors in the prostate gland, bladder neck, and urethra. This results in relaxation of the smooth muscle in these areas, which leads to improved urine flow and reduced symptoms of BPH.
Chemically, Naftopidil D7 is a deuterated derivative of Naftopidil, with seven deuterium atoms incorporated into its molecular structure. Deuterium is a stable isotope of hydrogen, and its incorporation into the drug molecule provides several advantages, including improved stability, decreased metabolic degradation, and increased bioavailability.
Naftopidil D7 is typically administered orally, with a recommended dosage of 25 mg per day. The drug is rapidly absorbed from the gastrointestinal tract and reaches peak plasma concentrations within two hours of administration. Naftopidil D7 is metabolized in the liver and excreted primarily in the urine.
Overall, Naftopidil D7 is a highly effective and well-tolerated treatment option for BPH. Its selective alpha-1 blocking activity and deuterated structure provide several advantages over other drugs in this class.
